SCOR (ENXTPA:SCR) Q3 Results Spotlight Profit Strength And Value Gap

SCOR came into this Q3 2026 print carrying a value label, with a P/E under 8x and a share price of €34.56 as of Friday’s close, well below one prominent €95.95 valuation marker. The headline this quarter is sheer profitability rather than growth. Net income reached €206 million, and the return on equity for the period was 20.4%, which is punchy for a reinsurer and hard to ignore. If the stock reaction felt muted to you, the earnings reality pointed to a business generating strong returns on capital while still priced as a bargain insurance play.

Like the look of SCOR’s 20.4% return on equity at a sub 8x P/E but want a few more high quality value plays to compare it against? Scan our 196 high quality undervalued stocks

Q3 2026 Earnings Summary

• Total Revenue (Q3 2026 vs. Q3 2025): €2,981 million vs. €3,004 million (slight decline)
• Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): €206 million vs. €217 million (decline)
• Basic EPS (Q3 2026 vs. Q3 2025): €1.15 vs. €1.22 (decline)
• Return on Equity, ROE (Q3 2026): 20.4% for the quarter, indicating profitability on shareholder capital

SCOR is thriving even as reinsurance prices start to slip. Ask Charlie what SCOR’s new plan assumes for softer pricing.

SCOR bull case: capital engine meets underwriting discipline

Optimists argue that SCOR’s data led underwriting and capital engine can keep earnings resilient even as markets get tougher.

"Analysts expect SCOR to keep using data driven underwriting and a broader business mix to support profitability and resilience as reinsurance demand reflects ongoing global volatility."

Q3 points in that direction. The P&C combined ratio at 84.1% sits comfortably below the 87% target, helped by low attritional losses and nat cat within budget. Life & Health has now delivered seven straight quarters in line with expectations, which backs the broader mix claim. Capital generation is visible in the 221% solvency ratio and 11.9% economic value growth YTD.

SCOR bear case: underwriting slippage and legal drag still in play

The sceptical view is that competitive pressure and legal frictions could erode this story faster than capital can replenish it.

"If pricing pressure intensifies or underwriting discipline weakens, net margins and earnings could be lower than this narrative assumes."

This quarter does not show that squeeze yet. P&C profitability remains strong and reserves were strengthened. Management is openly flagging softer pricing into Jan 2027 renewals though, so the risk is live rather than disproved. On legal exposure, the expected €50 million hit from Covéa is already flowing through cash flows, and management highlights that group solvency is unaffected, which limits immediate balance sheet stress.

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.

Hunt For Mispriced Earnings Power

SCOR shows how a strong quarter can still leave questions around what the market is truly rewarding. The real opportunity sits in finding stocks that could be undervalued before sentiment catches up.

• Company 1 - 41% below our estimate - uses a multi brand electric portfolio and overseas production to chase faster growth in exports and intelligent vehicles.
• Company 2 - 43% below our estimate - expands sterile injectable manufacturing and contract work so heavy R&D spending can feed into higher margin specialty treatments.
• Company 3 - 27% below our estimate - widens lending beyond microfinance into secured housing, business, gold and vehicle loans as digital platforms reshape how underbanked customers access credit.

Those are three of them. See the full list of 196 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com